Biocytogen Announces RenLite® Licensing Agreement with Janssen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Slate Asset Management Announces Partner and Managing Director Promotions10.12.2025 15:00:00 EET | Press release
Slate Asset Management (“Slate”), a global alternative investment platform focused on essential real estate and infrastructure, today announced three senior leadership promotions, effective January 1, 2026. Molly Mahoney has been elevated to Partner, and John Murray and Sayed M. Alaali have been promoted to Managing Directors. “Molly, John, and Sayed have demonstrated outstanding dedication, skill, and leadership over the years and each has contributed meaningfully to Slate’s reputation as a proven investor and a trusted partner to leading global institutions,” said Brady Welch, Co-Founding Partner at Slate. “We are very pleased to welcome them to the highest ranks of our firm’s leadership.” Blair Welch, Co-Founding Partner at Slate, added: “In a year of significant growth, these individuals have consistently delivered exceptional outcomes for Slate’s clients, partners, and communities. They are unwavering in their commitment to excellence, integrity, and teamwork, and we look forward
Kingswood Capital Management Enters Into a Definitive Agreement to Acquire Safran Passenger Innovations10.12.2025 15:00:00 EET | Press release
Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) announced today that it has entered into a definitive agreement to acquire Safran Passenger Innovations (“SPI” or the “Company”) from Safran, an international high-tech company operating in the aviation, defense, and space markets. SPI is a leading global provider of in-flight entertainment and connectivity solutions for airlines and airplane manufacturers worldwide. Matt Smith will continue to serve as SPI’s CEO, and the entire SPI leadership team will remain in place. The transaction is expected to close early next year, subject to customary legal and regulatory requirements. Headquartered in Brea, California, SPI created and designed an award-winning in-flight entertainment and connectivity platform known as RAVE, recognized for its intuitive design, reliability, and innovative approach. Kingswood’s acquisition of SPI is driven by a shared vision of positioning the company to deliver transformative, next-ge
Armis Partners with KODE Labs and IntelliBuild to Streamline Security Operations Across the Building Management Lifecycle10.12.2025 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced a strategic partnership with KODE Labs and IntelliBuild to help organizations unify cybersecurity, operational intelligence and governance for building lifecycle management. The joint offering combines Armis’ continuous asset intelligence with KODE Labs’ performance trends and analytics, which are then operationalized by IntelliBuild’s governance and reporting. By translating accurate, verified intelligence into accountable action, organizations can streamline the operations of building management systems – from thermostats, lighting and badge readers to elevator controllers and security cameras – and proactively strengthen their cyber defenses. “To achieve real security in the new age of connected environments, you must have comprehensive, real-time protection across the entire attack surface,” said Nadir Izrael, CTO and Co-Founder at Armis. “This integration addresses the growing complexity, risk and fragmentati
FiRa Unveils New Membership Tier to Fuel Industry Growth10.12.2025 15:00:00 EET | Press release
FiRa® Consortium is expanding its membership structure with a new Associate tier that opens the door to broader industry involvement. With new revenue-based pricing, organizations of all sizes can now more easily help shape the future of precise, secure wireless experiences. By reducing cost-related barriers and expanding access to FiRa resources, this new tier opens the door for innovators, developers, and emerging players to contribute to the next generation of wireless capabilities. The updated structure gives companies a more flexible and accessible path to Associate membership: $7,500 USD for companies with annual revenue below $50 million USD $30,000 USD for companies with annual revenue above $50 million USD The refreshed Associate tier maintains all existing benefits, including participation in FiRa Working Groups, access to specifications, engagement in FiRa Plugfests, product certification opportunities, and eligibility to apply as a FiRa Authorized Test Lab. These opportunit
QuantrolOx Unveils VIDYAQAR — the World’s First True Open-Architecture Quantum Platform for Education, Research, Testing and Benchmarking10.12.2025 14:29:00 EET | Press release
QuantrolOx today announced a major milestone in quantum technology with the launch of VIDYAQAR, the world’s first True Open-Architecture Quantum Platform designed specifically for education, research, testing, and benchmarking. The system was unveiled today in India and will be available globally in the first half of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210668898/en/ VIDYAQAR - A complete quantum platform with cryogenics, control hardware and QPU - powered by Quantum EDGE. The name VIDYAQAR derives from the Sanskrit Vidyākar, meaning “causing wisdom, giving knowledge or science”—a perfect reflection of the platform’s mission to widen access to advanced quantum hardware and accelerate innovation. A Complete, Open and Scalable Quantum Platform VIDYAQAR is a connected, fully open-architecture superconducting quantum system that brings together: CryogenicsControl electronicsQuantum Processing Unit (QPU)Integra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom